Access cutting-edge systemic lupus erythematosus treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access systemic lupus erythematosus specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related systemic lupus erythematosus treatment provided free
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C).
Sponsor: Amgen
Check if you qualify for this systemic lupus erythematosus clinical trial in New York, NY
If you're searching for systemic lupus erythematosus treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced systemic lupus erythematosus specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.